2015 HSC Section 1 Book of Articles

4. Walker CL, Rudan I, Liu L, et al. Global

burden of childhood pneumonia and

diarrhoea.

Lancet

. 2013;381(9875):1405

–

1416

5. Wald ER, Applegate KE, Bordley C, et al;

American Academy of Pediatrics. Clinical

practice guideline for the diagnosis and

management of acute bacterial sinusitis

in children aged 1 to 18 years.

Pediatrics

2013;132(1). Available at:

www.pediatrics. org/cgi/content/full/132/1/e262

6. Benninger M, Brook I, Farrell DJ. Disease

severity in acute bacterial rhinosinusitis

is greater in patients infected with

Streptococcus pneumoniae

than in those

infected with

Haemophilus in

uenzae

Otolaryngol Head Neck Surg

. 2006;135(4):

523

–

528

7. Lucero MG, Dulalia VE, Nillos LT, et al.

Pneumococcal conjugate vaccines for pre-

venting vaccine-type invasive pneumococ-

cal disease and X-ray de

ned pneumonia in

children less than two years of age.

Cochrane Database Syst Rev

. 2009; (4):

CD004977

8. Fitzwater SP, Chandran A, Santosham M,

Johnson HL. The worldwide impact of the

seven-valent pneumococcal conjugate vac-

cine.

Pediatr Infect Dis J

. 2012;31(5):501

–

508

9. Koshy E, Murray J, Bottle A, Sharland M,

Saxena S. Impact of the seven-valent pneu-

mococcal conjugate vaccination (PCV7)

programme on childhood hospital ad-

missions for bacterial pneumonia and

empyema in England: national time-trends

study, 1997

–

2008.

Thorax

. 2010;65(9):770

–

774

10. Nelson JC, Jackson M, Yu O, et al. Impact of

the introduction of pneumococcal conju-

gate vaccine on rates of community ac-

quired pneumonia in children and adults.

Vaccine

. 2008;26(38):4947

–

4954

11. Lee GE, Lorch SA, Shef

er-Collins S, Kronman

MP, Shah SS. National hospitalization trends

for pediatric pneumonia and associated

complications.

Pediatrics

. 2010;126(2):204

–

213

12. Elston JW, Santaniello-Newton A, Meigh JA,

et al. Increasing incidence of invasive

pneumococcal disease and pneumonia de-

spite improved vaccination uptake: sur-

veillance in Hull and East Yorkshire, UK,

2002

–

2009.

Epidemiol Infect

. 2012;140(7):

1252

–

1266

13. Benninger MS, Manz R. The impact of vac-

cination on rhinosinusitis and otitis media.

Curr Allergy Asthma Rep

. 2010;10(6):411

–

418

14. Shapiro DJ, Gonzales R, Cabana MD,

Hersh AL. National trends in visit rates

and antibiotic prescribing for children

with acute sinusitis.

Pediatrics

. 2011;127

(1):28

–

15. Fanella S, Singer A, Embree J. Presentation

and management of pediatric orbital cel-

lulitis.

Can J Infect Dis Med Microbiol

. 2011;

22(3):97

–

100

16. Stockholm County Child Healthcare Ser-

vices.

Annual Report

. Stockholm, Sweden:

Stockholm County Child Healthcare Ser-

vices; 2012

17. Regional Planning Of

ce. Of

cial statis-

tics, Stockholm County Council. Avail-

able at:

www.tmr.sll.se/Global/Dokument/ Statistik/Befolkningsutveckling/2012_1_s_ Befolkningsutvecklingen_2011.pdf

18. Wagner AK, Soumerai SB, Zhang F, Ross-

Degnan D. Segmented regression analysis

of interrupted time series studies in med-

ication use research.

J Clin Pharm Ther

2002;27(4):299

–

309

19. Gebski V, Ellingson K, Edwards J, Jernigan

J, Kleinbaum D. Modelling interrupted time

series to evaluate prevention and control

of infection in healthcare.

Epidemiol Infect

2012;140(12):2131

–

2141

20. Peña MT, Preciado D, Orestes M, Choi S.

Orbital complications of acute sinusitis:

changes in the post-pneumococcal vaccine

era.

JAMA Otolaryngol Head Neck Surg

2013;139(3):223

–

227

21. Benninger MS. Acute bacterial rhinosinusitis

and otitis media: changes in patho-

genicity following widespread use of

pneumococcal conjugate vaccine.

Otolar-

yngol Head Neck Surg

. 2008;138(3):274

–

278

22. McNeil JC, Hulten KG, Mason EO Jr, Kaplan

SL. Serotype 19A is the most common

Streptococcus pneumoniae

isolate in chil-

dren with chronic sinusitis.

Pediatr Infect

Dis J

. 2009;28(9):766

–

768

23. Feikin DR, Kagucia EW, Loo JD, et al; Sero-

type Replacement Study Group. Serotype-

speci

c changes in invasive pneumococcal

disease after pneumococcal conjugate

vaccine introduction: a pooled analysis of

multiple surveillance sites.

PLoS Med

. 2013;

10(9):e1001517

24. Brook I, Gober AE. Frequency of recovery of

pathogens from the nasopharynx of chil-

dren with acute maxillary sinusitis before

and after the introduction of vaccination

with the 7-valent pneumococcal vaccine.

Int

J Pediatr Otorhinolaryngol

. 2007;71(4):575

–

579

25. Magnus MC, Vestrheim DF, Nystad W,

et al. Decline in early childhood re-

spiratory tract infections in the Norwe-

gian mother and child cohort study after

introduction of pneumococcal conjugate

vaccination.

Pediatr Infect Dis J

. 2012;31

(9):951

–

955

26. Grif

n MR, Zhu Y, Moore MR, Whitney CG,

Grijalva CGUS. U.S. hospitalizations for

pneumonia after a decade of pneumococ-

cal vaccination.

N Engl J Med

. 2013;369(2):

155

–

163

27. Grijalva CG, Nuorti JP, Arbogast PG, Martin

SW, Edwards KM, Grif

n MR. Decline in

pneumonia admissions after routine child-

hood immunisation with pneumococcal

conjugate vaccine in the USA: a time-

series analysis.

Lancet

. 2007;369(9568):

1179

–

1186

28. Grijalva CG, Grif

n MR. Unveiling the bur-

den of in

uenza-associated pneumococcal

pneumonia.

J Infect Dis

. 2012;205(3):355

–

357

29. Viasus D, Paño-Pardo JR, Pachón J, et al;

Novel In

uenza A(H1N1) Study Group of the

Spanish Network for Research in Infectious

Diseases (REIPI). Pneumonia complicating

pandemic (H1N1) 2009: risk factors, clinical

features, and outcomes.

Medicine (Balti-

more)

. 2011;90(5):328

–

336

30. Weinberger DM, Simonsen L, Jordan R,

Steiner C, Miller M, Viboud C. Impact of the

2009 in

uenza pandemic on pneumococ-

cal pneumonia hospitalizations in the

United States.

J Infect Dis

. 2012;205(3):

458

–

465

31. Örtqvist A, Bennet R, Rinder MR, Lindblad H,

Eriksson M. Effectiveness of the monovalent

AS03-adjuvanted in

uenza A(H1N1)pdm09

vaccine against hospitalization in children

because of in

uenza.

Vaccine

. 2012;30(39):

5699

–

5702

32. Madhi SA, Klugman KP; Vaccine Trialist

Group. A role for

Streptococcus pneumo-

niae

in virus-associated pneumonia.

Nat

Med

. 2004;10(8):811

–

813

33. Weinberger DM, Givon-Lavi N, Shemer-Avni

Y, et al. In

uence of pneumococcal vaccines

and respiratory syncytial virus on alveolar

pneumonia, Israel.

Emerg Infect Dis

. 2013;

19(7):1084

–

1091

34. Grijalva CG, Zhu Y, Nuorti JP, Grif

n MR.

Emergence of parapneumonic empyema in

the USA.

Thorax

. 2011;66(8):663

–

668

35. Grijalva CG, Nuorti JP, Zhu Y, Grif

n MR.

Increasing incidence of empyema compli-

cating childhood community-acquired pneu-

monia in the United States.

Clin Infect Dis

2010;50(6):805

–

813

36. Burgos J, Falcó V, Pahissa A. The increasing

incidence of empyema.

Curr Opin Pulm

Med

. 2013;19(4):350

–

356

37. Li ST, Tancredi DJ. Empyema hospital-

izations increased in US children despite

pneumococcal conjugate vaccine.

Pediat-

rics

. 2010;125(1):26

–

PEDIATRICS Volume 134, Number 6, December 2014

141